Pfizer will pay $850m for rights to Merck cancer drug

Deal aims to accelerate German company’s move into oncology treatments in the US

Pfizer will pay $850 million for rights to a cancer drug being developed by Merck.
Pfizer will pay $850 million for rights to a cancer drug being developed by Merck.

Pfizer will pay $850 million for rights to a cancer drug being developed by Merck, in a move that will accelerate the German company's move into oncology treatments in the US.

The agreement also calls for Pfizer to pay as much as $2 billion to Merck if the drug, meets commercial and regulatory goals, Germany-based Merck said in a statement today.

Pfizer lowered its forecast for 2014 earnings to reflect the $850 million upfront payment.

The drug is a so-called immunotherapy that aims to use the body’s immune system to fight tumors. Merck said in September it was seeking a partner for the product, which it’s studying in lung and ovarian cancer.

READ MORE

The two companies will jointly fund research and commercialization costs for the medicine, and also agreed to co-promote Pfizer’s Xalkori medicine in the US and other markets.

Reuters